[미국특허]
Method for delivery of somatostatin into a lumen of the intestinal tract
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/31
A61K-009/00
A61M-025/10
A61M-005/00
A61K-031/155
A61M-031/00
A61K-009/48
출원번호
US-0009601
(2016-01-28)
등록번호
US-9814763
(2017-11-14)
발명자
/ 주소
Imran, Mir
출원인 / 주소
Incube Labs, LLC
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
8인용 특허 :
66
초록▼
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
대표청구항▼
1. A method for delivering a somatostatin compound to a patient, said method comprising: providing a solid somatostatin or somatostatin analogue dosage shaped as a tissue penetrating member; penetrating the tissue penetrating member into an intestinal wall after oral ingestion, wherein the somatosta
1. A method for delivering a somatostatin compound to a patient, said method comprising: providing a solid somatostatin or somatostatin analogue dosage shaped as a tissue penetrating member; penetrating the tissue penetrating member into an intestinal wall after oral ingestion, wherein the somatostatin or somatostatin analogue is released into the blood stream from the solid dosage somatostatin in the intestinal wall. 2. The method of claim 1, wherein the somatostatin or somatostatin analogue released into the blood stream from the solid dosage somatostatin or somatostatin analogue reaches a Cmax in a shorter time period than a time period to achieve a Cmax for an extravascularly injected dose of somatostatin or somatostatin analogue. 3. The method of claim 2, wherein a tmax for the somatostatin or somatostatin analogue released from the solid dosage somatostatin or somatostatin analogue is less than about 80% of a tmax for the extravascularly injected dose of somatostatin or somatostatin analogue. 4. The method of claim 2, wherein a tmax for the somatostatin or somatostatin analogue released from the solid dosage somatostatin or somatostatin analogue is less than about 50% of a tmax for the extravascularly injected dose of somatostatin or somatostatin analogue. 5. The method of claim 2, wherein a tmax for the somatostatin or somatostatin analogue released from the solid dosage somatostatin or somatostatin analogue is less than about 30% of a tmax for the extravascularly injected dose of somatostatin or somatostatin analogue. 6. The method of claim 2, wherein a tmax for the somatostatin or somatostatin analogue released from the solid dosage somatostatin or somatostatin analogue is less than about 10% of a tmax for the extravascularly injected dose of somatostatin or somatostatin analogue. 7. The method of claim 1, wherein the tissue penetrating member is inserted into a wall of the small intestine. 8. The method of claim 1, wherein the solid somatostatin or somatostatin analogue dosage is orally delivered in a swallowable capsule. 9. The method of claim 8, penetrating the tissue penetrating member into the intestinal wall comprises operably coupling the tissue penetrating member to a delivery means having a first configuration wherein the tissue penetrating member is within the capsule and a second configuration wherein the tissue penetrating member is advanced out of the capsule and into the intestinal wall. 10. The method of claim 9, wherein penetrating the tissue penetrating member into the intestinal wall comprises expanding at least one expandable balloon from the first to the second configuration. 11. The method of claim 1, wherein the solid dosage somatostatin or somatostatin analogue comprises a biodegradable material which degrades within the intestinal wall to release somatostatin or somatostatin analogue into the blood stream. 12. The method of claim 11, wherein the biodegradable material comprises PGLA, a sugar or maltose. 13. The method of claim 11, wherein the solid dosage somatostatin or somatostatin analogue comprises at least one pharmaceutical excipient. 14. The method of claim 13, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant. 15. The method of claim 14, wherein the binder comprises PEG. 16. The method of claim 1, wherein a weight per cent of somatostatin or somatostatin analogue in the solid dosage somatostatin or somatostatin analogue is the range between about 0.3 to 8%. 17. The method of claim 1, wherein a dose of somatostatin or somatostatin analogue in the solid dosage somatostatin is in a range from about 50 to 600 mg. 18. The method of claim 1, wherein the somatostatin analogue is octreotide. 19. The method of claim 18, wherein a dose of octreotide in the preparation is in a range from about 10 to100 μg. 20. The method of claim 1, further comprising retaining the solid dosage somatostatin within the intestinal wall after insertion. 21. The method of claim 20, wherein retaining comprises anchoring at least one of a barb or an inverse taper shape of the solid dosage somatostatin or somatostatin analogue in the intestinal tissue. 22. The method of claim 1, wherein penetrating the tissue penetrating member comprises applying a force to the tissue penetrating member, wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by such application of force. 23. The method of claim 1, wherein the solid dosage somatostatin or somatostatin analogue produces a long-term release of somatostatin or somatostatin analogue. 24. The method of claim 1, wherein the Cmax achieved by delivering the solid dosage somatostatin or somatostatin analogue into the intestinal wall is at least about 10 times greater than the Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall. 25. The method of claim 24, wherein the condition is a pH. 26. The method of claim 24, wherein the somatostatin or somatostatin analogue dosage is in solid form. 27. A method for delivering a somatostatin or somatostatin analogue to a patient, said method comprising: providing a somatostatin or somatostatin analogue dosage within a swallowable capsule having at least one tissue penetrating member having a lumen; delivering the somatostatin or somatostatin analogue dosage into a wall of the small intestine from the capsule via the tissue penetrating member lumen and an application of force on the somatostatin or somatostatin analogue dosage, the delivery of the somatostatin or somatostatin analogue being effectuated responsive to a condition unique to the small intestine, and wherein the somatostatin or somatostatin analogue is released into the blood stream from the dosage of somatostatin or somatostatin analogue in the wall of the small intestine.
Wright Jeremy C. (Los Altos CA) Eckenhoff James B. (Los Altos CA) Maruyama Frederick H. (San Jose CA) Peery John R. (Stanford CA), Delivery system comprising means for controlling internal pressure.
Lewkowicz,Shlomo; Gat,Daniel; Kraizer,Yehudit; Gilad,Zvika; Leuw,David; Meron,Gavriel; Glukhovsky,Arkady, Device and method for examining a body lumen.
Hugemann Berhhard (Frankfurt am Main DEX) Schuster Otto (Bad Soden DEX), Device for the release of substances at defined locations in the alimentary tract.
Pasricha Pankaj J. (Columbia MD) Kalloo Anthony N. (Glenndale MD), Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction.
Imran, Mir; Herrmann, Peter; Syed, Baber; Williams, Timothy H.; Ong, Chang Jin; Method, Greg, Device, system and methods for the oral delivery of therapeutic compounds.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Yokoi,Takeshi; Takizawa,Hironobu; Segawa,Hidetake; Adachi,Hideyuki, Encapsulated medical device and method of examining, curing, and treating internal region of body cavity using encapsulated medical device.
Lehmann Grard (Neuville de Poitou FRX) Metais Jol (Monts Sur Guesnes FRX) Meunier Jean-Francois (Noisy le Grand FRX) Gautier Jean-Philippe (Ozoir la Ferriere FRX), Implantable drug-dispensing capsule and system facilitating its use.
Truex Buehl E. (Glendora CA) Gibson Scott R. (Granada Hills CA) Weinberg Alvin H. (Moorpark CA), Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly.
Brister, Mark C.; Quintana, Nelson; Patel, Kaushik A.; Drake, Neil R.; Llevares, Antonio C.; Markovic, Dubravka; Rasdal, Andrew P.; VandenBerg, Amy D. L., Intragastric device.
Saffran Murray (Toledo OH) Neckers Douglas C. (Perrysburg OH), Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointest.
Nicolaides Ernest D. (Ann Arbor MI) Tinney Francis J. (Ann Arbor MI) Kaltenbronn James S. (Ann Arbor MI) DeJohn Dana E. (Ann Arbor MI) Lunney Elizabeth A. (Ann Arbor MI) Roark W. Howard (Ann Arbor MI, Modified tripeptides.
Eckenhoff ; deceased James B. ; Holladay Leslie A. ; Leonard ; Jr. John Joseph ; Leung Iris K. M. ; Tao Sally A. ; Magruder Judy A. ; Carr John P. ; Wright Jeremy, Peptide/protein suspending formulations.
Imran, Mir, Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.